Herpes simplex virus thymidine kinase (HSVTK) with ganciclovir (GCV) is currently the most widely used suicide gene/prodrug system in cancer gene therapy. A major limitation in this therapy is the inefficient activation of GCV by HSVTK to its active antimetabolites. We described earlier two strategies to overcome this limitation: (1) generation of HSVTK mutants with improved GCV activation potential and (2) construction of a fusion protein encoding HSVTK and mouse guanylate kinase (MGMK), the second enzyme in the GCV activation pathway. As a means to further enhance GCV activation, two MGMK/HSVTK constructs containing the HSVTK mutants, mutant 30 and SR39, were generated and evaluated for their tumor and bystander killing effects in vitro and in vivo. One fusion mutant, MGMK/30, shows significant reduction in IC 50 values of approximately 12 500-fold, 100-fold, and 125-fold compared with HSVTK, mutant 30 or MGMK/HSVTK, respectively. In vitro bystander analyses show that 5% of MGMK/30-expressing cells are sufficient to induce 75% of tumor cell killing. In an xenograft tumor model, MGMK/30 displays the greatest inhibition of tumor growth at a GCV concentration (1 mg kg
Introduction
Thymidine kinase (TK) (EC 2.7.1.21) is an important enzyme in the pyrimidine salvage pathway, catalyzing the transfer of the g-phosphate from ATP to thymidine to produce deoxythymidine monophosphate (dTMP). 1 Unlike human TK, herpes simplex virus type 1 (HSV-1) thymidine kinase (HSVTK) has a broad substrate specificity and is able to phosphorylate pyrimidines, pyrimidine analogues (thymidine, deoxycytidine, and azidothymidine), and guanosine analogues (ganciclovir (GCV), acyclovir, buciclovir, and penciclovir). Originally suggested by Moolten, HSVTK has become widely used as a suicide gene in combination with the guanosine analogue GCV for the treatment of a variety of cancers. 2, 3 On successful delivery of HSVTK to cancer cells followed by systemic administration of GCV, transfected cancer cells become sensitized to the prodrug. Inside the cell, GCV is initially phosphorylated by HSVTK to form GCV-monophosphate (GCV-MP), which is then further phosphorylated to GCV-diphosphate (GCV-DP) by cellular guanylate kinase (GMK) and to the active antimetabolite GCV-triphosphate by cellular nucleoside diphosphokinase. 4, 5 Cytotoxicity is mainly because of the action of GCV-triphosphate after its incorporation into nascent DNA, which results in inhibition of DNA synthesis and ultimately leads to cell death. 5, 6 As human TK has a narrow substrate specificity and is not active toward GCV, prodrug-associated cytotoxicity is limited to the site of transfection. As low gene transfer is a key limitation in gene therapy, the success of suicide gene therapy relies heavily on a phenomenon known as the bystander effect, in which untransfected neighboring cancer cells are eradicated by the transfer of antimetabolites through gap junctions or apoptotic vesicles. 2, 7 Earlier studies reported that complete tumor ablation in vivo could be achieved in the presence of GCV even when only a small percentage of the tumor was transfected by retroviral vectors carrying the HSVTK gene. 8 Implicit in the bystander effect is that sufficient phosphorylated GCV is transferred to neighboring cells to elicit cell killing. In addition, an immune-related response also contributes to the bystander effect although in a delayed manner.
Although the bystander effect promotes tumor cell killing in HSVTK/GCV gene therapy, inefficient activation of GCV by HSVTK is a major limitation. The K m value of HSVTK toward GCV (K m ¼ 47 mM) is approximately 100-fold higher than its K m value for thymidine (K m ¼ 0.4 mM), its natural substrate. 9 This lower GCV binding ability is exacerbated by a five-fold lower k cat (turnover rate) resulting in more than a 500-fold lower overall enzyme catalytic efficiency (k cat /K m ). Owing to the combination of low gene transfer and inadequate GCV activation by HSVTK, myelosuppressive doses of GCV are required to achieve significant or complete tumor ablation. 9 The second step in the activation of GCV is performed by GMK (ATP:GMP phosphotransferase, EC 2.7.4.8). GMK is an essential enzyme involved in purine biosynthesis and is responsible for the phosphorylation of GMP and dGMP, as well as GCV-MP. 10 Earlier reports have shown the K m value of GMK for GCV-MP is twofold higher (K m ¼ 42-54 mM) than its K m toward its natural substrate GMP (B25 mM). 10, 11 This suggests that endogenous GMK may be a second rate limiting step during the production of sufficient antimetabolites for complete tumor ablation. 12, 13 One approach to improve prodrug activation, which may consequently reduce the dose of GCV required to kill tumor cells and thereby limit the prodrug-associated negative side effects, is to use HSVTK mutants with increased activity and/or substrate specificity toward GCV. 9, 14 We have reported earlier the construction and characterization of two such HSVTK mutants, mutant 30 and SR39, that show not only an improvement in kinetic properties toward GCV, but also in vitro tumor cell killing and in vivo tumor growth inhibition compared with HSVTK alone. 9, 15 As a means to overcome the bottleneck of prodrug activation from the monophosphate to the diphosphate form, a fusion protein expressing both functional GMK and HSVTK (GMK/HSVTK) was generated. 16 Mouse GMK (MGMK) was used because, in our hands, the mouse enzyme was soluble in Escherichia coli whereas the human enzyme was not. 10 In vitro cytotoxic assays using this fusion protein showed that cells expressing MGMK/HSVTK confer a B175-fold decrease in IC 50 value compared with HSVTK alone in response to GCV treatment in stably transfected rat C6 glioma cells. 16 In this study, we evaluated tumor toxicity and bystander killing activity of the previously created fusion MGMK/HSVTK in vitro and in an in vivo tumor model.
Results from in vivo studies reported here, suggest that the fusion protein inhibits tumor growth at a GCV concentration (1 mg kg
À1
) that has no affect on wild-type HSVTK-bearing tumors. Moreover, the fusion also elicits a stronger bystander effect in vitro and in vivo. To further augment its GCV-mediated tumor killing activity, we have taken a further step by engineering the improved HSVTK mutants, mutant 30 and SR39, into the fusion protein construct. Here, we report that the mutant fusion proteins created in this study exhibit a superior GCVmediated toxicity and bystander killing activity at very low doses of prodrug in vitro and in an in vivo xenograft tumor model compared with MGMK/HSVTK and their respective single gene constructs. The results show that the mutant chimeric proteins offer significant advantages to the suicide gene therapy approach to that of the widely used wild-type HSVTK gene, previously characterized HSVTK mutants, or the previously created MGMK/ HSVTK fusion construct.
Materials and methods

Materials
Oligonucleotides used to mutate and sequence HSVTK were obtained from Integrated DNA Technologies (Coralville, IA). Restriction endonucleases and T4 DNA ligase were purchased from New England Biolabs (Beverly, MA). DNA purification was carried out using several kits: Wizard PCR prep kits from Promega (Madison, WI), HiSpeed Plasmid Mini kit from Qiagen (Valencia, CA), and StrataPrep EF Plasmid Midikit from Stratagene (La Jolla, CA). Alamar Blue was purchased from Serotec Limited (Oxford, UK). All cell culture reagents were purchased from Gibco (Carlsbad, CA). All other reagents were purchased from Sigma (St Louis, MO) unless otherwise noted.
Bacterial strains
lac were used as a recipient for certain cloning procedures. E. coli strain TS202A(DE3) (LAM À , tdk-1, IN(rrnD-rrnE)1, ilv À 276 kan R ara À ), a TK-deficient and a conditional GMK-deficient strain, was used in genetic complementation assays to assess TK and GMK activity. 17 Construction of mgmk/TK fusion mutant constructs and genetic complementation Construction of pET23d:mgmk/TK fusion mutant constructs was carried out as described earlier by Willmon et al. (2006) . 16 Briefly, the mouse gmk (mgmk) gene was isolated from pET23d:mgmk as an BglII/MscI fragment and ligated to BglII/MluI (blunt ended)-digested pET23d:30 or pET23d:SR39. The resulting plasmids, designated pET23d:mgmk/30 and pET23d:mgmk/SR39, were confirmed by DNA sequencing. For complementation studies, E. coli strain TS202A(DE3) harboring pET23d, pET23d: mgmk, pET23d:HSVTK, pET23d:mgmk/TK pET23d: mgmk/30, or pET23d:mgmk/SR39 were grown at 37 1C on either GMK complementation media or TK complementation media as described earlier. 14, 17 Construction of mammalian expression vectors The pET23d:mgmk, pET23d:SR39, pET23d:mgmk/ HSVTK, pET23d:mgmk/30, and pET23d:mgmk/SR39 were subcloned into pUB6/V5-HisB (Invitrogen, Carlsband, CA) digested with EcoRV as NcoI (blunt ended) fragments. After restriction enzyme verification, DNA sequencing analysis confirmed the presence of the mgmk, SR39, mgmk/ HSVTK, mgmk/30, and mgmk/SR39 genes. The resulting plasmids were designated pUB:mgmk, pUB:SR39, pUB:mgmk/HSVTK, pUB:mgmk/30, and pUB:mgmk/ SR39, respectively. To expedite the construction of mammalian vectors, site-directed mutagenesis was performed on plasmid pUB:SR39 to introduce mutations derived from mutant 30 or to revert the sequence back to wild-type HSVTK using the QuikChange site-directed mutagenesis kit from Stratagene according to the manufacturer's protocol. 
Cell lines
Cell lines were maintained in a humidified incubator at 37 1C in 5% CO 2 . Rat C6 glioma cells (C6) were purchased from ATCC (Manasass, VA) and were grown in Dulbecco's Modified Essential Medium containing 5% fetal bovine serum, 1 mM sodium pyruvate, 10 mM HEPES, 100 mM nonessential amino acids, 100 U ml À1 penicillin G, 10 mg ml À1 streptomycin sulfate, 292 mg ml À1 L-glutamine, 100 mM sodium citrate, and 0.0014% NaCl. Transfected cells were cultured in media supplemented with blasticidin at a concentration of 4 mg ml À1 for selection of stably transfectants.
In vitro cytotoxicity assay One mg of each DNA: pUB (empty vector), pUB:mgmk, pUB:HSVTK, pUB:30, pUB:SR39, pUB:mgmk/HSVTK, pUB:mgmk/30, and pUB:mgmk/SR39 was used to transfect 1 Â 10 5 rat C6 glioma cells by lipofection using FuGENE 6 transfection reagent (Roche Diagnostic, Penzberg, Germany) at a 3:1 ratio as described by the manufacturer. Protein expression levels were determined by immunoblot analyses as described earlier. 16 The membrane was probed with rabbit polyclonal HSVTK or mgmk antibody and followed by goat anti-rabbit-APconjugated antibody. Color reaction was developed using the AP Conjugate Substrate kit (Bio-Rad, Hercules, CA). The in vitro cytotoxicity assays were performed using stable transfectants confirmed by immunoblot. Pools of transfectants were transferred to 96-well microtiter plates at an initial density of 500 cells per well. On cell adherence overnight, GCV (0-100 mM) was added in sets of eight wells for each concentration tested. The cells were subjected to GCV for 7 days, at which time the redox indicator dye Alamar Blue was added. Cell survival was determined by fluorescence recorded at a 530/590 nm, using a multidetector microplate reader Biotek Synergy HT (Winooski, VT), several hours later as described by the manufacturer and data were plotted with the standard deviation. At least three replicates were performed.
In vitro bystander experiment Rat C6 glioma cells stably transfected with pUB (empty vector) were mixed at different ratios with stable transfectants harboring either pUB:HSVTK, pUB:30, pUB:SR39, pUB:mgmk/HSVTK, pUB:mgmk/30 or pUB: mgmk/SR39. The mixed cells were then transferred to 96-well microtiter plates at a final density of 500 cells per well and after cell adherence overnight, a GCV concentration of 80 mM was added into the cells. Cell survival was determined as described above.
Xenograft tumor model
Pools of C6 glioma cells stably transfected with pUB, pUB:HSVTK, pUB:30, pUB:SR39, pUB:mgmk/HSVTK, pUB:mgmk/30, or pUB:mgmk/SR39 (0.5 Â 10 6 cells in 200 ml of PBS at pH 7.2) were injected subcutaneously into 5-to 6-week-old female nude mice (n ¼ 5 for each group) (Athymic NCr-nu/nu; National Cancer Institute, Frederick, MD). Bystander xenograft tumor model experiments were carried out in a similar manner except nude mice (n ¼ 5) were injected with pools of C6 glioma cells stably transfected with pUB (empty vector) that were mixed with pools of C6 glioma cells stably transfected with either pUB:HSVTK, pUB:30, pUB:SR39, pUB: mgmk/HSVTK, pUB:mgmk/30 or pUB:mgmk/SR39 at a ratio of 95:5 (vector:suicide gene). When the tumors reached 3-4 mm in diameter (day 0), PBS or GCV at 1 or 0.1 mg kg À1 was administered by intraperitoneal injection twice a day for 8 consecutive days. Starting at day 0, the tumor volume was monitored using caliper measurement (length, width, and height) every other day until day 16 at which time the mice were euthanized. Tumor volume was calculated using the formula: 4/3p ((width Â length Â height)/2). Tumor volume was plotted and analyzed for statistical significance using Student's t-test.
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Results
Genetic complementation
Two new constructs were generated, MGMK/30 (containing HSVTK mutant 30) and MGMK/SR39 (containing HSVTK mutant SR39). To ascertain whether the constructed mutant fusions displayed functional TK and GMK activity, genetic complementation for both activities was independently evaluated using the previously established TK (tdk -) and conditionally gmk-deficient E. coli strain TS202A(DE3). 17 On DNA sequence verification, pET23d, pET23d:mgmk, pET23d:HSVTK, pET23d:30, pET23d:SR39, pET23d:mgmk/HSVTK, pET23d:mgmk/30, and pET23d:mgmk/SR39 were used to transform the E. coli strain, TS202A(DE3) and were plated onto TK and GMK selection media in the presence or absence of arabinose supplemented with kanamycin. As anticipated, cells harboring pET23d and pET23d: mgmk were not able to complement the TK deficiency of TS202A(DE3), whereas cells harboring pET23d:HSVTK, pET23d:30, pET23d:SR39, and their respective fusion constructs were viable (data not shown). Similarly, only pET23d:mgmk, pET23d:mgmk/HSVTK, pET23d:mgmk/30, and pET23d:mgmk/SR39 were viable on GMK selection medium in the absence of arabinose (data not shown). These results indicated that the fusion proteins were expressed and maintained both TK and GMK activities. All cultures grew on control non-selective minimal medium.
In vitro prodrug sensitivity assays
To analyze the efficacy of the constructed mutant chimeric proteins, we used rat C6 glioma cells. Rat C6 glioma cells have earlier served as a model system to evaluate the efficacy of the HSVTK/GCV paradigm. 18, 19 Mammalian expression vectors (pUB) expressing suicide genes were constructed and used to stably transfect rat C6 glioma cells. Once stable transfection was achieved, expression levels of the suicide proteins were assessed by immunoblots using polyclonal serum raised against HSVTK or MGMK. Immunoblots showed the presence of HSVTK at around 45 kDa when anti-HSVTK serum was used, and MGMK at around 23 kDa when anti-MGMK serum was used. These results are in accord with the predicted molecular masses for each protein (Figures 1a and b) . The fusion proteins cross-reacted with both anti-sera at the predicted molecular mass of approximately 68 kDa and relatively equivalent protein levels were observed (Figure 1c) . In vitro prodrug sensitivity assays were carried out as described in the 'Materials and methods' section and shown as percent survival in Figure 2 . This experiment was performed at least three times using different pools of transfectants with similar results. In the presence of GCV, wild-type HSVTK-expressing cells displayed an IC 50 Figure 3 shows results from this experiment as percent survival. This experiment was performed at least three times using different pools of transfectants with similar results. In the presence of GCV, all fusion constructs elicited stronger bystander effects Figure 1 Immunoblots of stable C6 transfectants. Equivalent amounts of cell lysates (B1 million cells) were collected from pools of stable transfectants harboring (a) pUB and pUB:mgmk, or (b) pUB:HSVTK, pUB:30, and pUB:SR39, or (c) pUB:mgmk/HSVTK, pUB:mgmk/30, and pUB:mgmk/SR39 were loaded onto an SDScontaining polyacrylamide gel. The proteins were transferred to nitrocellulose and an immunoblot was performed using rabbit anti-HSVTK and anti-MGMK serum. The presence of MGMK, HSVTK (and HSVTK mutants), and MGMK/HSVTK (and the remaining fusion constructs) were detected at B23, B45, and B68 kDA, respectively, which was in accord with the expected molecular weight for each enzyme. Relatively equivalent protein levels were observed.
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Results indicate that MGMK/SR39 shows the strongest bystander activity. When only B1% of tumor cells expressed MGMK/SR39, 60% tumor killing was achieved. This is a significant improvement over SR39 alone, where B40% of tumor cell transduction was necessary to achieve the same killing effect. MGMK/30 showed the second strongest bystander activity where only B5% cells expressing fusion proteins were sufficient to induce about 75% of tumor cell killing. Mutant 30, SR39 and wild-type fusion MGMK/HSVTK seemed to have similar bystander activities, where approximately 50% cell transduction resulted in 65% tumor ablation.
Xenograft tumor model
In vivo analyses of all constructs were conducted as described in the 'Materials and methods' section. Figure 4 displays the time course of tumor growth in mice (E) were evaluated for GCV sensitivity as described in the 'Materials and methods' section. After 7 days of GCV treatment, cell survival was determined using Alamar Blue according to the manufacturer's instructions. Untreated samples (0 mM GCV) were set at 100% cell survival. Each data point (mean±s.e.m.; n ¼ 3; performed with 24 replicates) is expressed as a percentage of the value for control wells with no GCV treatment. (Figure 4a ). However, once GCV injections were stopped, rapid tumor growth was observed in these groups of mice. In contrast, mice bearing MGMK/30-expressing tumors and treated with GCV displayed the greatest restriction in tumor growth (day 16 mean tumor volume: 50.8 mm 3 ) ( Table 2 ). This is an (Figure 4b ; Table 3 ) (PX0.05).
As no difference in tumor growth inhibition was observable between SR39 and MGMK/SR39, another in vivo xenograft tumor studies using one-tenth the dose of GCV or 0.1 mg kg À1 was performed (Figure 4c ). When 0.1 mg kg À1 GCV was used to treat nude mice bearing SR39-or MGMK/SR39-expressing tumor cells, a difference in tumor growth was observed starting on day 4 and continued up to day 14 (GCV treatment was stopped on day 8) (Figure 4c ). At the lower dose of GCV, the efficacy to inhibit tumor growth was discernable and results show that MGMK/SR39 generated a more potent GCV-mediated tumor growth impairment compared with SR39 alone (Figure 4c) Bystander xenograft tumor model Following protocols described in the 'Materials and methods' section, a mixture of cells expressing empty vector and cells harboring the tested constructs at a ratio 95:5, respectively, was injected into nude mice. The bystander activity of these constructs was analyzed in an in vivo xenograft tumor model and results are shown in Figures 5 and 6 . In the presence of GCV, MGMK/ 30 exhibited substantial bystander killing activity as indicated by the greatest inhibition in tumor growth. On the other hand, HSVTK, MGMK/HSVTK, and mutant 30 did not exhibit sufficient bystander activity able to suppress tumor growth (Figure 5a ). Tumors from mice receiving PBS treatment all grew at approximately the same rate (Figure 5b) . In a separate series of experiments, the bystander activity of SR39 and MGMK/SR39 was evaluated. In the presence of 1 mg kg À1 GCV, MGMK/ SR39 generated a slightly stronger bystander effect compared with SR39 alone as indicated by a more restricted tumor growth in mice bearing MGMK/SR39-expressing cells (Figure 6a ). When PBS was used, tumors from all mice group grew at approximately the same rate with no statistical difference (Figure 6b ).
Discussion
Despite apparent progress, conventional treatments against cancer such as chemotherapy and radiotherapy still face limitations and place heavy tolls on patients. Systemic administration of chemotherapy not only affects and kills normal tissues, consequently causing unpleasant side effects, but can also lead to the appearance of secondary cancers. 20, 21 Suicide gene therapy is an attractive alternative treatment for cancer because it offers the prospect of selectively introducing genes into cancer cells, rendering them susceptible to specific antimetabolites, and thereby limits the antitumor effect to tumor sites. 7 HSVTK/GCV is the most extensively 
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A Ardiani et al studied and described suicide gene/prodrug system in suicide gene therapy. In contrast to human TK, HSVTK is able to phosphorylate select antiviral and anticancer drugs, such as the antiviral drug GCV. The efficacy and antitumor effect of HSVTK/GCV has been well documented in vitro and in vivo with more than 70 clinical trials conducted. 3 As of June 2007, three of these trials have advanced to phase III multicenter programs. 22, 23 The selectivity of suicide gene therapy to target cancer cells is primarily because of the vector or delivery vehicle. Unfortunately, successful, selective, and effective delivery of suicide genes remains one of the most challenging ) or (b) PBS was administered twice a day for 8 days. During this period, tumor growth was measured every other day. Tumor volume was calculated using the formula 4/3p ((width Â length Â height)/2), plotted and analyzed for statistical significance using Student's t-test. Asterisks denote statistical significance (Pp0.05) in tumor sizes between mice harboring 5% of MGMK/SR39-expressing tumor cells and those that received 5% of either HSVTK-, MGMK/HSVTK-, or SR39-expressing tumor cells in the presence of 1 mg kg À1 GCV. ) or (b) PBS was administered twice a day for 8 days. During this period, tumor growth was measured every other day. Tumor volume was calculated using the formula 4/3p ((width Â length Â height)/2), plotted and analyzed for statistical significance using Student's ttest. Asterisks denote statistical significance (Pp0.05) in tumor sizes between mice harboring 5% of MGMK/30-expressing tumor cells and harboring either 5% of HSVTK-, mutant 30-, or MGMK/HSVTKexpressing tumor cells in the presence of 1 mg kg À1 GCV.
Fusion of guanylate kinase and HSV-1 thymidine kinase mutants A Ardiani et al factors in gene therapy. This problem is exacerbated by another major limiting factor: the low efficiency and efficacy of suicide enzymes toward the prodrugs. Owing to these limitations, a potent bystander effect is crucial to achieve significant or complete tumor ablation. 24 The bystander effect associated with suicide gene therapy is achieved through two different mechanisms: local or immune mediated. 7 In the local-mediated bystander effect, gap junctions have an important function to transfer phosphorylated GCV to neighboring cells. 18 The transfer of toxic drugs through gap junctions has some limitations as certain type of tumors have been reported to downregulate intracellular gap junction communication and thus may have disorganized and/or nonfunctional gap junctions. 7, 25 These tumors show extremely poor bystander effects. Throughout this study, we chose to perform both in vitro and in vivo GCVsensitivity studies in rat C6 glioma cells because of their low levels of intracellular communication by gap junctions. 18 By using rat C6 cells, we sought to show that despite the nature of these cells having poor gap junctions, the fusion constructs are still able to generate broader and stronger bystander killing effects by generating higher levels of antimetabolites compared to their single gene or wild-type fusion constructs. Local-mediated bystander effects can also be achieved through the transfer of apoptotic vesicles containing toxic metabolites to neighboring nontransfected cells. 7 An increase in the amount of cytotoxic products, because of improved prodrug conversion by the suicide genes, will likely lead to more pronounced bystander effects through apoptotic vesicle transfer as well.
One strategy to enhance therapeutic response of HSVTK toward GCV is by improving enzyme activity and efficiency toward to the prodrug. Earlier, several HSVTK mutants with significant improvement toward GCV were generated and characterized. Two mutants in particular, mutant 30 and SR39, were analyzed in depth both in vitro and in an in vivo tumor model. 9, 15 Mutant SR39 contains five amino-acid changes, whereas mutant 30 contains six amino-acid substitutions; most of these changes are located at or near the active site. In vitro analyses showed that both mutants enhanced rat C6 glioma cell sensitivity to GCV by more than 200-fold. When both mutants were evaluated in vivo, significant tumor growth inhibition was observed at a dose that does not affect wild-type HSVTK. Clearly, both of these HSVTK mutants have significant advantages over wild-type HSVTK.
Earlier reports have suggested that a bottleneck problem arises in the HSVTK/GCV system, leading to accumulation of the ineffective intermediate products, that is, GCV-MP and GCV-DP. 4, 16 We hypothesize that this bottleneck problem occurs because endogenous GMK is limited in its ability to convert GCV-MP to GCV-DP. Indeed, the K m value of GMK for GCV-MP is approximately two-fold higher than its K m value for its natural substrate guanosine monophosphate (GMP). 10, 11 This implies that higher expression of GMK is required to overcome the bottleneck problem to produce higher amounts of active antimetabolites. Earlier experiments co-expressing HSVTK and GMK as separate proteins failed to show notable improvements in GCV sensitivity (data not shown. 26 We hypothesized that the creation of a fusion enzyme may alleviate this problem by creating more efficient and more rapid drug conversion to the active antimetabolites form. We created a fusion chimeric gene, encoding both HSVTK and MGMK activities and showed a significant reduction in IC 50 value in rat C6 glioma cells compared with HSVTK alone in the presence of GCV. 16 This study was aimed to evaluate the antitumor and bystander killing activity of the previously described fusion protein MGMK/HSVTK in vitro and in vivo, and to further augment its antitumor activity by replacing the wild-type HSVTK portion of the fusion construct with the sequences of the well established HSVTK mutants, mutant 30 and SR39. Current in vitro cytotoxic assay data validate the earlier finding that wild-type fusion MGMK/HSVTK sensitized rat C6 glioma cells to GCV. However, in our current findings, we observed approximately a 100-fold reduction in IC 50 value. This slight discrepancy in IC 50 value (less than twofold) may be due to different mammalian promoters used in the earlier study (pREP8D7) compared with this study (pUB), and therefore protein levels may differ accordingly. Here, the bystander activity of the wild-type fusion enzyme was analyzed in vitro and exhibited a stronger bystander effect than HSVTK alone. This suggests that the presence of higher levels of GMK intracellularly in close proximity to HSVTK may be important in producing sufficient antimetabolite levels able to eradicate transfected cancer cells and neighboring non-HSVTKexpressing tumor cells.
When mutant 30 was used to replace wild-type HSVTK in the fusion construct, there was an improvement in tumor ablation and bystander activity. In the presence of GCV, a 100-fold decrease in IC 50 was observed in MGMK/30-expressing tumor cells compared with mutant 30-expressing cells, translating in a total of 12 500-fold reduction in IC 50 compared with HSVTK-expressing cells. When MGMK/30-expressing cells were seeded into nude mice and treated with 1 mg kg À1 GCV, no tumor growth was observed during GCV treatment period (days 0-8) up to 8 days after GCV treatment ended (day 16). Mice harboring mutant 30-and MGMK/HSVTKexpressing tumor cells showed a delay in tumor growth during the GCV treatment period. Perhaps the most revealing finding was the exceptional improvement in the bystander activity of MGMK/30-expressing cells. The MGMK/30-transfected cells showed a substantial bystander killing effect in vitro and were able to achieve complete tumor cell killing when only B25% of cells expressed the fusion enzyme. This was approximately a three-fold improvement over mutant 30 and MGMK/ HSVTK, where about a 75% transfected cell population was necessary to completely eradicate the cells. In a xenograft tumor model, MGMK/30-expressing tumor cells at a vector to suicide gene ratio of 95:5 showed a highly potent GCV-mediated bystander antitumor activity compared with mutant 30-or MGMK/HSVTKexpressing tumor cells, in which tumors grew similar to those in PBS-treated mice. The absence of bystander killing effect could be attributed to the low dose of GCV (1 mg kg À1 ), short duration of prodrug treatment, and/or to the low level (5%) of MGMK/30-expressing cells used to evaluate the bystander activity. Slow tumor growth was observed in mice harboring 5% MGMK/30-expressing tumor cells during GCV treatment. Such bystander killing effects in rat C6 glioma cells is in fact impressive given that these cells are notorious for their low levels of gap junctions. This further implies that in rat C6 cells, a high amount of active antimetabolites is required to achieve significant bystander activity. Furthermore, the use of immunocompromised (nude) mice in this study is likely to preclude the full extent of the bystander effect because of the deficiency of the immune-mediated component of this phenomenon.
A 2500-fold or 25-fold reduction in IC 50 was detected between cells expressing either SR39 or MGMK/SR39 and those expressing HSVTK or MGMK/HSVTK, respectively. However, in vitro prodrug sensitivity assays showed no statistical difference in IC 50 value between MGMK/SR39-and SR39-expressing cells. A similar pattern emerged in vivo where both groups of mice harboring either MGMK/SR39-or SR39-expressing tumor cells showed a relatively equal restriction in tumor growth when dosed with 1 mg kg À1 GCV. When the lower dose of GCV (0.1 mg kg
À1
) was used, however, a statistically significant difference in GCV-mediated tumor killing could be observed; mice seeded with MGMK/SR39-expressing tumor cells experienced a delay in tumor growth compared with those that received SR39-expressing cells. The impediment in tumor growth seen during the in vivo bystander studies between mice harboring MGMK/SR39-expressing cells and those that received SR39-expressing cells when dosed with 1 mg kg À1 GCV was marginal but statistically significant.
MGMK/30 shows significant improvement in tumor killing and bystander activity compared with mutant 30, whereas only a minor improvement was observed in MGMK/SR39 compared with SR39. One possible explanation for this trend is the difference in kinetic properties toward GCV and thymidine exhibited by mutant 30 and SR39. When GCV is used as substrate, the K m of mutant 30 is seven-fold higher than that of wildtype HSVTK. Additionally, the turnover rate (k cat ) of mutant 30 for GCV is approximately six-fold lower than wild type, which subsequently translates to a 41-fold reduction in overall enzyme catalytic efficiency. 9 Therefore, one might predict that mutant 30 would not elicit a greatly enhanced prodrug sensitivity to cells. However, because endogenous thymidine (natural substrate of HSVTK) competes with the prodrug for the active site, it is important to consider the kinetic parameter mutant 30 displays toward thymidine. Indeed, mutant 30 shows much poorer activity toward thymidine when compared with wild-type HSVTK. When thymidine is used as a substrate, mutant 30 shows approximately a 3000-fold reduction in overall enzyme catalytic efficiency compared with wild-type HSVTK. 9 Mutant SR39, on the other hand, has an advantage over mutant 30 in regard to enzyme activity toward GCV as indicated by a 14-fold improvement in K m value for GCV compared with HSVTK.
1 Although SR39's activity toward thymidine is slightly impaired, as shown in the 173-fold lower overall enzyme catalytic efficiency, its impairment is not nearly as dramatic as that of mutant 30 (3000-fold). This latter point may provide an explanation for the observed difference in MGMK/30 and MGMK/SR39 tumor killing efficacy. On the basis of kinetic data, mutant 30-expressing cells are likely to generate lower amounts of GCV-MP than SR39-expressing cells. The current findings with MGMK/30 show that the combination of MGMK and mutant 30 shows a much more striking improvement in tumor killing compared with that of SR39. Therefore, taken together the combination of MGMK and mutant 30 may provide a 'balancing' effect to the system, in which mutant 30 generates adequate amounts of GCV-MP to be shunted directly to MGMK and efficient phosphorylation of GCV-MP to GCV-DP is achieved. However, because MGMK/SR39 is very efficient at producing GCV-MP, owing to the improved actions of SR39 toward GCV, conversion to GCV-DP becomes limited as MMGK is unable to convert the excessive amounts of GCV-MP to GCV-DP efficiently.
The lack of complete tumor eradication seen in these studies is likely due to the short duration of GCV treatment (compared with other reports of 14-21 days of treatment). Furthermore, the GCV doses used in this study (0.2-2 mg kg À1 per day) are between 150-and 1500-fold lower than the doses used in most animal experiments (up to 300 mg kg À1 per day). 7 A higher dose of GCV combined with a longer GCV treatment is likely to result in complete tumor eradication when used in concert with MGMK/30 and MGMK/SR39. In the end, enzymes with high catalytic activity can impact cell killing efficacy directly by generating a more active prodrug or indirectly through a broader bystander effect. The use of superior fusion enzymes offers significant advantages over wildtype HSVTK, HSVTK mutants, or MGMK/HSVTK in at least two important ways: (a) by enhancing GCVmediated cell killing and bystander killing effects and (b) by further reducing the amount of myelosuppressive GCV required for effective cell killing. Ultimately, the application of such novel fusion enzymes will likely improve the clinical outcome of suicide gene therapy in cancer patients and compensate for the inefficient and ineffective problems associated with current delivery methods.
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